Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.
Wang M, Zhang Z, Liu J, Song M, Zhang T, Chen Y, Hu H, Yang P, Li B, Song X, Pang J, Xing Y, Cao Z, Guo W, Yang H, Wang J, Yang J, Wang C.
Wang M, et al.
Signal Transduct Target Ther. 2022 May 13;7(1):157. doi: 10.1038/s41392-022-00959-3.
Signal Transduct Target Ther. 2022.
PMID: 35551173
Free PMC article.
Notably, the phosphorylation of EGFR (p-EGFR) and SYK (p-SYK) were identified as potential therapeutic targets in the progression of silicosis. To inhibit and validate these targets, we tested fostamatinib (targeting SYK) and Gefitinib (targeting EGFR), and both drugs effe …
Notably, the phosphorylation of EGFR (p-EGFR) and SYK (p-SYK) were identified as potential therapeutic targets in the progression of silicos …